P35.22 WITHDRAWN
Lintao Wang,Xiaonan Liu,Xue Yu,Ziqi Zhao,Yong Zhang,Yi Bai,Shujun Zhang,Youlong Xu,Pan Zhao,Hong Bao,Xinqiang Wang,Ruifeng Liu,Ruochen Xu,Jingjing Xiang,Hanliang Jiang,Yan Jiang,Xuesong Wu,Yi Shao,Liang Ji,Qiong Wu,Zulin Zhang,Shuai Lü,Shenglin Ma
DOI: https://doi.org/10.1016/j.jtho.2021.01.723
IF: 20.121
2021-01-01
Journal of Thoracic Oncology
Abstract:pulmonary lymphoepithelioma-like carcinoma (PLELC), a rare subtype of non-small cell lung cancer (NSCLC).However, the understanding of the treatment for EBV-infected NSCLC was still elusive.Immunotherapy that targets PD-1/PD-L1 has been utilized as a novel clinical treatment in recent years.Here, we focus on the genomic landscapes of lung cancers with EBV-infection and its correlation with PD-L1.Methods: Patients with both PD-L1 expression detection and genomic information were screened in HapLab database.HaploX 605-gene panel sequencing, covering 1.31 MB genome, was performed to analyze the genomic data of patients.PD-L1 expression was detected by immunochemistry.Bioinformatic analysis of genomic mutations and the correlation with the expression of PD-L1 were studied.Results: We analyzed the genomic profiles of 23 EBV-infected NSCLC patients.11 cases of lung squamous-cell carcinoma (LUSC), 4 cases of lung adenocarcinoma (LUAD), 5 cases of lung pulmonary lymphoepithelioma-like carcinoma (PLELC), and 3 unidentified cases were included in this study.Collectively, 93 genome mutations of 67 genes were detected in 23 EBV-infection cases.Top 3 frequently mutated genes were TP53 (27%), CSMD3 (18%) and KMT2D (18%).The EBV-infected patients exhibited a low level of tumor mutation burden (TMB).The median TMB was 1.53 Muts/MB (ranging from 0 to 14.5 Muts/MB).Only 3 of 23 patients (13.0%) harbored the canonical driver mutations in NSCLC.Interestingly, 10/23 patients (43.5%) showed high expression of PD-L1, while 13/23 patients (56.5%) showed low expression.We also assessed the expression of PD-L1 in lung cancers with no EBV-infection (867 cases).Only 118/867 (13.6%) patients without EBV-infection presented high PD-L1 expression, while 749/867 (86.4%) presented low PD-L1 expression.Conclusion: EBV-infection can occur in different kinds of NSCLC, including LUSC, LUAD, and PLELC.TMB and driver mutations of EBV-infected NSCLC were not frequently observed as normal lung cancers, implying a different mechanism leading to EBVinfected lung cancers.Interestingly, EBV-infected NSCLC tended to have a high correlation with the expression of PD-L1.This may give a hint on the application of checkpoint blockade immunotherapy on EBV-infected NSCLC.